GlassScriptPhysician profile
Sato Mananian
NPI 1932736261
$7,368.81
in general payments reported to CMS, 2019-2025
11 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.31 · 2021: $19.04 · 2022: $1,579 · 2023: $588 · 2024: $4,943 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,752.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visioneering Technologies, INC. | $4,372.82 | 2024 | |
| Johnson & Johnson Vision Care, INC. | $809.58 | 2022-2025 | Acuvue |
| Alcon Vision LLC | $533.27 | 2020-2024 | Precision 1 |
| Sight Sciences, INC. | $458.15 | 2022-2023 | Omni Surgical System |
| Bausch & Lomb Americas INC. | $422.43 | 2022-2023 | Infuse, Miebo |
| Coopervision INC. | $157.68 | 2022-2025 | Myday Contact Lens, Misight Contact Lens |
| Novartis Pharmaceuticals Corporation | $133.05 | 2021-2022 | |
| Oyster Point Pharma, INC. | $123.37 | 2022 | |
| Allergan, INC. | $122.59 | 2022 | |
| Apellis Pharmaceuticals, INC. | $120.39 | 2024 | Syfovre |
| Astellas Pharma US INC | $115.48 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sato Mananian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.